Skip to main content

NIDDK Announces Proteomics/Metabolomics Project in Type 2 Diabetes

NEW YORK, March 19 (GenomeWeb News) - The National Institute of Diabetes and Digestive and Kidney Diseases announced today that it will commit $1 million in FY 2005 to fund projects devoted to using proteomic and metabolomic techniques to develop a diagnostic for type 2 diabetes.


Applicants can request funding for two years under the R21 mechanism, followed by three years under the R33 mechanism. The application receipt date for this PAR is July 20, 2004.


In addition to funding, the NIDDK will provide to investigators plasma from diverse individuals for use in validation experiments. Plasma from three types of patients will be provided: those who have been diagnosed with type 2 diabetes; those who have impaired glucose tolerance, and those who have normal glucose tolerance.


The newest PAR is one of several that the NIDDK has issued over the past couple of years inviting investigators to apply proteomics to the study of diabetes.


The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.